DIXI medical

Marchaux, FranceFounded 1988101–250 employeesdiximedical.comLinkedIn

Epilepsy

DIXI medical designs and manufactures high-precision medical devices in France, specializing in intracerebral electrodes for stereo-electroencephalography (SEEG). With more than 50 years of expertise, it supports clinicians in diagnosing and treating drug-resistant epilepsy and serves epilepsy centers in over 40 countries.

Visit diximedical.com ↗

Founded: 1988
Employees: 101–250

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

Recent highlights

The company said the change was intended to increase operational flexibility, restore margins, and preserve competitive pricing. A separate hiring signal describes the company as building a U.S. sales team to support the shift; no individual hires or named leadership changes are identified. DIXI medical’s product focus remains intracerebral electrodes for stereoelectroencephalography (SEEG), including the MICRODEEP® Micro-Macro Depth Electrode, designed to record single-unit neural activity during SEEG procedures. The company also describes its broader work as designing and manufacturing devices for functional and stereotactic neurosurgery, with particular relevance to epilepsy diagnosis.

Market position

DIXI medical occupies a specialized medical-device niche: intracerebral electrodes and related equipment used in SEEG, a procedure for locating epileptic foci in people with drug-resistant focal epilepsy. Its profile combines manufacturing and microtechnology expertise with a narrowly defined clinical use case, rather than a broad portfolio of general neurology devices. The MICRODEEP® electrode adds deployable micro-contacts for recording single-unit neural activity, a specific capability that distinguishes it within the company’s stated product range. NeuroPace is relevant as DIXI medical’s former U.S. distribution partner, not as a confirmed direct competitor. DIXI medical says it serves epilepsy centers in more than 40 countries and works with clinicians and researchers. Its return to direct U.S. sales, announced in April 2025, signals a move toward greater control of customer relationships and margins.

Growth & opportunities

DIXI medical’s trajectory is shaped by a long operating history and a recent commercial-channel change, rather than by disclosed venture financing or a sequence of dated product launches. Founded in 1988, the company has developed a focused business around intracerebral electrodes and devices for functional and stereotactic neurosurgery. Its MICRODEEP® Micro-Macro Depth Electrode reflects continued product specialization, combining macro-electrode contacts with deployable micro-contacts for neural recording during SEEG. The clearest inflection point in the available company-specific timeline is the Apr 3, 2025 announcement that DIXI medical planned to restart direct U.S. sales in Q4 2025 after ending its distribution partnership with NeuroPace. The stated rationale—operational flexibility, margin recovery, and competitive pricing—suggests a commercial reset, while the accompanying hiring signal points to investment in a U.S. sales team.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes DIXI medical distinct

reccy insights

What makes DIXI medical distinct

01More than 50 years of experience in microtechnology and functional neurosurgery.
02Specializes in high-precision SEEG electrodes for care involving drug-resistant epilepsy.
03Designs and manufactures medical devices in France using controlled cleanroom processes.
04Works with neurosurgeons, neurologists, and researchers to develop clinically focused solutions.
05Supplies epilepsy centers in more than 40 countries and supports SEEG programs with training and education.

Technology & products2

Technology & products

MICRODEEP® Micro-Macro Depth Electrode
A multi-contact, flexi-rigid intracerebral depth electrode with deployable micro-contacts for recording single-unit neural activity during SEEG procedures.
SEEG (Stereoelectroencephalography) Diagnostic Procedure
A minimally invasive diagnostic procedure using intracerebral electrodes to localize epileptic foci in patients with drug-resistant focal epilepsy.

Intracerebral electrodes for stereoelectroencephalography (SEEG).
MICRODEEP® Micro-Macro Depth Electrode with deployable micro-contacts for single-unit neural recording.
High-precision medical-device design and manufacturing.

Recent updates1

Launches, partnerships and team changes from press coverage

Apr 3, 2025Partnership
DIXI medical announced it would resume direct sales in the U.S. market starting in Q4 2025 after ending its distribution partnership with NeuroPace. The stated aims were greater operational flexibility, restored margins, and competitive pricing.
einpresswire.com

In the Cortex

Experience a New Paradigm in Thermocoagulationdiximedical.com · Feb 5, 2026

About DIXI medical

Products: MICRODEEP® Micro-Macro Depth Electrode, SEEG (Stereoelectroencephalography) Diagnostic Procedure
Focus areas: Neurotechnology, medical devices, diagnostics, research tools, hardware, SEEG, epilepsy, neurosurgery
Headquarters: Marchaux, France
Founded: 1988
Employees: 101–250
Patents granted: 3 (Crunchbase)
Trademarks: 2